Literature DB >> 26260866

Tuberculosis (HIV-negative people): improving adherence.

Liliya Eugenevna Ziganshina1, Michael Eisenhut.   

Abstract

INTRODUCTION: About one third of the world's population has immunological evidence of previous exposure to Mycobacterium tuberculosis. In 2013, an estimated 9.0 million people developed tuberculosis (TB) and 1.5 million died from the disease. METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical questions: What are the effects of directly observed treatment (DOT) versus self-administered treatment (SAT) in people with tuberculosis without HIV infection? What are the effects of support mechanisms for DOT in people with tuberculosis without HIV infection? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2014 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview).
RESULTS: At this update, searching of electronic databases retrieved 189 studies. After deduplication and removal of conference abstracts, 104 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 86 studies and the further review of 18 full publications. Of the 18 full articles evaluated, three systematic reviews and one RCT were added at this update. We performed a GRADE evaluation for 12 PICO combinations.
CONCLUSIONS: In this systematic overview, we categorised the efficacy for 13 interventions based on information relating to the effectiveness and safety of directly observed treatment and support mechanisms for directly observed treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26260866      PMCID: PMC4531336     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  13 in total

1.  Directly observed therapy and treatment adherence.

Authors:  J Volmink; P Matchaba; P Garner
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

2.  Incentives vs outreach workers for latent tuberculosis treatment in drug users.

Authors:  C K Malotte; J R Hollingshead; M Larro
Journal:  Am J Prev Med       Date:  2001-02       Impact factor: 5.043

3.  Increasing return compliance in a tuberculosis detection drive.

Authors:  S K Wurtele; A N Galanos; M C Roberts
Journal:  J Behav Med       Date:  1980-09

4.  Exploring the efficacy of a case management model using DOTS in the adherence of patients with pulmonary tuberculosis.

Authors:  Chia-Ju Hsieh; Li-Chan Lin; Benjamin Ing-Tiau Kuo; Chi-Huei Chiang; Wei-Juin Su; Jen-Fu Shih
Journal:  J Clin Nurs       Date:  2008-04       Impact factor: 3.036

5.  Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial.

Authors:  James N Newell; Sushil C Baral; Shanta B Pande; Dirgh Sing Bam; Pushpa Malla
Journal:  Lancet       Date:  2006-03-18       Impact factor: 79.321

Review 6.  Long term efficacy of DOTS regimens for tuberculosis: systematic review.

Authors:  Helen S Cox; Martha Morrow; Peter W Deutschmann
Journal:  BMJ       Date:  2008-02-04

Review 7.  Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment.

Authors:  Qin Liu; Katharine Abba; Marissa M Alejandria; David Sinclair; Vincent M Balanag; Mary Ann D Lansang
Journal:  Cochrane Database Syst Rev       Date:  2014-11-18

8.  Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste.

Authors:  Nelson Martins; Peter Morris; Paul M Kelly
Journal:  BMJ       Date:  2009-10-26

9.  A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

Review 10.  Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review.

Authors:  Mweete D Nglazi; Linda-Gail Bekker; Robin Wood; Gregory D Hussey; Charles S Wiysonge
Journal:  BMC Infect Dis       Date:  2013-12-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.